ivermectin long-acting injectable / Monash University, The Peter Doherty Institute for Infection and Immunity - LARVOL DELTA

SAIVE: A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention (clinicaltrials.gov) - P2 | N=400 | Recruiting | Sponsor: MedinCell S.A

New P2 trial • Infectious Disease • Novel Coronavirus Disease

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial. (PubMed, PLoS Negl Trop Dis) - P=N/A | "IDA was well tolerated and more effective than DA for clearing Mf. Widespread use of this regimen could accelerate LF elimination in PNG."

Journal • Infectious Disease

Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. (PubMed, Biochim Biophys Acta Mol Basis Dis) - "Thereafter, we discuss IVM's mechanism and highlight the clinical advantages that could potentially contribute towards disabling the viral replication of SARS-CoV-2. In summary, the collective review of recent efforts suggests that IVM has a prophylactic effect and would be a strong candidate for clinical trials to treat SARS-CoV-2."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Ophthalmology • Respiratory Diseases • STAT3

Diagnostic accuracy of a novel enzyme-linked immunoassay for the detection of IgG and IgG4 against Strongyloides stercoralis based on the recombinant antigens NIE/SsIR. (PubMed, Parasit Vectors) - "The NIE-SsIR IgG ELISA demonstrated better accuracy than the IgG4 assay and was deemed promising particularly for serosurveys in endemic areas."

Journal

Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. (PubMed, Am J Ther) - No abstract available

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease

Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. (PubMed, PLoS Negl Trop Dis) - "Recent evidence suggests that, in some foci, elimination of onchocerciasis from Africa may be feasible with mass drug administration (MDA) of ivermectin...The formidable scale of data collection required to map onchocerciasis endemicity across the African continent presents an opportunity to use spatial data to identify areas likely to be suitable for onchocerciasis transmission. National onchocerciasis elimination programmes may wish to consider prioritising these IUs for mapping surveys as human resources, laboratory capacity, and programmatic schedules may constrain survey implementation, and possibly delaying MDA initiation in areas that would ultimately qualify."

Journal • Infectious Disease

Prophylaxis against covid-19: living systematic review and network meta-analysis. (PubMed, BMJ) - "The first iteration of this living network meta-analysis includes nine randomised trials-six of hydroxychloroquine (n=6059 participants), one of ivermectin combined with iota-carrageenan (n=234), and two of ivermectin alone (n=540), all compared with standard care or placebo. Two trials (one of ramipril and one of bromhexine hydrochloride) did not meet the sample size requirements for network meta-analysis...This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication."

Journal • Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Researchers say common anti-parasite drugs can kill coronavirus in less than 48 hours (Gotech Daily) - "Researchers in Australia report that Ivermectin, an FDA-approved drug commonly used to treat parasites, appears to be effective in treating the coronavirus SARS-COV-2 (COVID-19). Medicines are widely available and may be 'reappropriated' for this application....Monash University in Melbourne that reported that Ivermectin appears to be effective in inhibiting COVID-19-causing coronavirus."

Clinical